Related Experiment Videos
Assessing the benefits of lipid-lowering therapy
1Joan and Sanford I. Weill Medical College of Cornell University, New York, New York 10021, USA.
Insights
Lipid-lowering therapy effectively prevents coronary artery disease. Landmark studies like 4S and WOSCOPS have eased safety concerns regarding these treatments for dyslipidemia.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Growing evidence supports lipid-lowering therapy for coronary artery disease (CAD) prevention.
- Management of dyslipidemia is recommended for at-risk patients.
- Early studies raised safety concerns regarding lipid intervention due to mortality rates.
Purpose of the Study:
- To review epidemiologic evidence for lipid modification in CAD prevention.
- To discuss important clinical trials and meta-analyses.
- To evaluate the cost-effectiveness of lipid-modifying treatments.
Main Methods:
- Review of epidemiologic data.
- Analysis of landmark clinical trials (e.g., 4S, WOSCOPS).
- Inclusion of meta-analyses on lipid-lowering therapy.
Main Results:
- Substantial evidence now supports lipid-lowering therapy for CAD prevention.
- Key studies (4S, WOSCOPS) have addressed and alleviated safety concerns.
- Lipid modification is increasingly endorsed for at-risk populations.
Conclusions:
- Lipid-lowering therapy is a safe and effective strategy for preventing coronary artery disease.
- Evidence from major trials supports its use in managing dyslipidemia.
- Cost-effectiveness further supports the implementation of these treatments.
Abstract:
In recent years, a substantial body of evidence has emerged to support the use of lipid-lowering therapy in the prevention of coronary artery disease, and many physician groups have endorsed the management of dyslipidemia in at-risk patients. An important consideration in such endorsements has been the issue of the safety of lipid intervention; many early primary- and secondary-prevention studies reported either no reduction in all-cause mortality rates or an increase in non-coronary artery disease mortality rates in treated patients. These observations raised serious concerns about the safety of such therapy. However, 2 landmark studies, the Scandinavian Simvastatin Survival Study (4S) and the West of Scotland Coronary Prevention Study (WOSCOPS), have contributed greatly to alleviating these concerns. In this article, a review of the epidemiologic evidence supporting the use of lipid modification will be presented, including important trials and meta-analyses, and the cost-effectiveness of lipid-modifying treatment will be discussed.